Australia as a first GTM for SaMD
Three reasons why I often recommend Australia as a first market for Software as a Medical Device are all on display in the guidance the TGA released this February and March. If you're building at the borderline between wellness and SaMD and hesitating to commit to the regulated path, this is worth five minutes of your attention.
1. It's written for the people who actually have to use it
The guidance is drafted for founders and product developers, built around the question they're actually asking: do I qualify, and what do I need to do? The language is plain, the format is genuinely readable, and the examples are plentiful — a BMI calculator versus a diabetes-diagnosis feature, spelled out function by function rather than left as an abstract principle. TGA's own FAQ walks through exactly this kind of case: an app with a calculator function and a diagnostic function needs each function assessed separately, because one is excluded and the other isn't.
That distinction matters commercially. Companies comply early when they don't need to hire a regulatory consultant just to understand the rules in the first place. Even if you're never planning to launch in Australia, the format itself is transferable — genuinely more accessible than anything comparable on the European Commission's or FDA's website, where the same information exists but is scattered across guidance documents written for regulators, not founders.
2. The carve-outs for low-risk software are real, not theoretical
TGA's framework has two distinct tiers below full regulation, and both are far more generous than anything under EU MDR/IVDR or even the IMDRF risk classification model most jurisdictions loosely follow.
Excluded means TGA doesn't regulate the product at all. The February–March 2026 guidance clarifies exclusions for digital mental health tools (evidence-based CBT-style apps and websites, provided they reference established clinical guidelines transparently within the product), general health and wellness software, health alert software, and health self-management software. The digital mental health exclusion in particular got detailed clarification in March 2026, spelling out the conditions a product must meet — including that it can't rely on proprietary treatment approaches outside recognised Australian clinical practice.
Exempt means the product is still legally a medical device, but with a minimal compliance burden and no ARTG (Australian Register of Therapeutic Goods) registration required. The clearest example is Clinical Decision Support Software — tools that help a clinician without replacing their judgment. Exempt CDSS still has to meet TGA's Essential Principles, carry appropriate labelling, and report adverse events, but skips the full registration pathway that would apply in most other markets.
Put together, a substantial share of what would be squarely regulated SaMD in the EU can market in Australia against a much lower bar. That's not TGA being lax — it's TGA being deliberate about where regulatory attention actually needs to go.
3. The regulator backs the low bar with real enforcement
This is the part people underestimate. TGA isn't just lowering the barrier for compliant low-risk software — it's actively enforcing the boundary for products that should be inside the regulated perimeter but aren't. The February–March 2026 guidance sits inside a broader compliance push, confirmed publicly as one of three coordinated actions: a clarified regulatory framework, active enforcement against non-compliant AI-enabled digital health software, and continued guidance development. I've been on the receiving end of TGA's enforcement personally, and can confirm it's been fair and procedurally reasonable — no drama, clear expectations, room to respond.
Is active enforcement a reason to enter a market, rather than a reason to avoid it? I'd argue yes, specifically because the rules here are accessible and the bar for compliant low-risk products is genuinely low. A regulator willing to enforce its own framework is a regulator that's levelling the playing field — you're not competing against companies quietly trading on non-compliance while you carry the cost of doing it properly.
Why this matters beyond Australia
I've written before about what other jurisdictions can learn from a more personal, accessible approach to regulator-industry interaction, and TGA is a recurring example in that conversation. The pattern here is consistent: clear self-assessment tools, proportionate low-risk pathways, and enforcement that backs up the framework rather than leaving it as guidance-only theatre. It's a combination that's genuinely rare — most regulators are strong on one or two of those three, not all three at once.
A practical suggestion
If you're at the wellness/SaMD borderline and hesitant to commit to a full regulated pathway anywhere yet, consider Australia as the first regulated market rather than the last. The self-assessment process itself is a useful diagnostic — even if you ultimately don't launch there, working through TGA's exclusion and exemption criteria will sharpen your own understanding of your product's risk classification before you face the more demanding compliance operations of the EU, US, or other markets. Build readiness in parallel; don't wait for a harder market to force the exercise on you.
References
Therapeutic Goods Administration (TGA), Understanding how we regulate software-based medical devices, guidance updated February 2026
Therapeutic Goods Administration (TGA), Understanding the general health or wellness software exclusion, and TGA Clarifies Exclusion for Digital Mental Health Software, guidance updated March 2026
Therapeutic Goods Administration (TGA), Understanding clinical decision support system software regulation — exemption criteria for CDSS
Align MT, Australia's TGA Signals What's Coming for AI in Healthcare, February 2026 — on the coordinated enforcement action alongside the guidance update
Giulia Paggiola, What can we learn from… Australia?, Edge Compliance blog — edgecompliance.co/blog/what-if-the-interaction-with-regulators-was-more-personal
Methodology note: This article is based on my original LinkedIn post (link), reflecting my professional experience advising companies on Software as a Medical Device strategy in Australia and internationally. AI assisted in elaborating the topic into a broader article by integrating background research and regulatory references on TGA's February–March 2026 guidance. All analysis and regulatory perspectives are my own, and all content has been reviewed by me for accuracy.
